WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2018107131) METHYLPHENIDATE-PRODRUGS, PROCESSES OF MAKING AND USING THE SAME
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.:    WO/2018/107131    International Application No.:    PCT/US2017/065481
Publication Date: 14.06.2018 International Filing Date: 09.12.2017
IPC:
C07D 401/12 (2006.01), C07F 9/59 (2006.01)
Applicants: KEMPHARM, INC. [US/US]; 2500 Crosspark Road, Suite E126 Coralville, Iowa 52241 (US)
Inventors: MICKLE, Travis; (US).
GUENTHER, Sven M.; (US).
CHI, Gouchen; (US)
Agent: GALLAGHER, Priscilla F.; (US)
Priority Data:
62/432,675 11.12.2016 US
62/519,629 14.06.2017 US
Title (EN) METHYLPHENIDATE-PRODRUGS, PROCESSES OF MAKING AND USING THE SAME
(FR) PROMÉDICAMENTS MÉTHYLPHÉNIDATES, PROCÉDÉS DE FABRICATION ET UTILISATION ASSOCIÉS
Abstract: front page image
(EN)The present technology is directed to d-threo-methylphenidate conjugates and a composition comprising d-threo-methylphenidate conjugated to nicotinoyl-L-serine, or salt thereof. The present technology also relates to a composition comprising at least one conjugate of d-methylphenidate having at least two or more chiral centers. The composition is optically active. The present technology additionally relates to oral formulations and pharmaceutical kits comprising at least one d-threo-methylphenidate conjugate. The pharmaceutical kit may comprise a specified amount of individual doses in a package. Each individual dose in the package may contain a pharmaceutically effective amount of a conjugate of d-threo methylphenidate.
(FR)La présente invention concerne des conjugués de d-thréo-méthylphénidate et une composition comprenant du d-thréo-méthylphénidate conjugué à la nicotinoyl-L-sérine, ou un sel de celle-ci. La présente invention concerne également une composition comprenant au moins un conjugué de d-méthylphénidate ayant au moins deux centres chiraux ou plus. La composition est optiquement active. La présente invention concerne en outre des formulations orales et des kits pharmaceutiques comprenant au moins un conjugué de d-thréo-méthylphénidate. Le kit pharmaceutique peut comprendre une quantité spécifiée de doses individuelles dans un emballage. Chaque dose individuelle dans l'emballage peut contenir une quantité pharmaceutiquement efficace d'un conjugué de d-thréo méthylphénidate.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)